1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013

Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 44 pages

Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Carcinoma. Non-Small Cell Lung Carcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Non-Small Cell Lung Carcinoma.
- A review of the Non-Small Cell Lung Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Non-Small Cell Lung Carcinoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Carcinoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Non-Small Cell Lung Carcinoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Non-Small Cell Lung Carcinoma 7
Non-Small Cell Lung Carcinoma Therapeutics under Development by Companies 9
Non-Small Cell Lung Carcinoma Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Non-Small Cell Lung Carcinoma Therapeutics - Products under Development by Companies 14
Non-Small Cell Lung Carcinoma Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Non-Small Cell Lung Carcinoma Therapeutics Development 16
Genentech, Inc. 16
Cancer Research Technology Limited 17
CureVac GmbH 18
Axelar AB 19
ImmunoFrontier, Inc. 20
Non-Small Cell Lung Carcinoma - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
AXL-1717 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
CHP-MAGE-A4 Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
diaziquone - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Revercom - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Drug Targeting Pan-PIM Kinase - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Drugs Targeting RAS Mutant Tumours - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
BV-6 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
SIMM-559 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
CV-9202 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Non-Small Cell Lung Carcinoma Therapeutics - Drug Profile Updates 37
Non-Small Cell Lung Carcinoma Therapeutics - Discontinued Products 39
Non-Small Cell Lung Carcinoma Therapeutics - Dormant Products 40
Non-Small Cell Lung Carcinoma - Product Development Milestones 41
Featured News and Press Releases 41
Aug 07, 2013: Interim Results of the GALAXY-1 Trial to be Presented at Best of ASCO 41
Aug 24, 2012: US Court Of Appeals Upholds Validity Of Lilly's Alimta Compound Patent 41
Jun 04, 2012: Xcovery Presents Phase I Clinical Results Of X-82 At ASCO 2012 Annual Meeting 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44



List of Tables

Number of Products Under Development for Non-Small Cell Lung Carcinoma, H2 2013 7
Products under Development for Non-Small Cell Lung Carcinoma - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Clinical Stage Development, H2 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Genentech, Inc., H2 2013 16
Cancer Research Technology Limited, H2 2013 17
CureVac GmbH, H2 2013 18
Axelar AB, H2 2013 19
ImmunoFrontier, Inc., H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 25
Non-Small Cell Lung Carcinoma Therapeutics - Drug Profile Updates 37
Non-Small Cell Lung Carcinoma Therapeutics - Discontinued Products 39
Non-Small Cell Lung Carcinoma Therapeutics - Dormant Products 40



List of Figures

Number of Products under Development for Non-Small Cell Lung Carcinoma, H2 2013 7
Products under Development for Non-Small Cell Lung Carcinoma - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Early Clinical Stage Products, H2 2013 12
Discovery and Pre-Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 21
Assessment by Route of Administration, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Molecule Type, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 25



Companies Mentioned

Genentech, Inc.
Cancer Research Technology Limited
CureVac GmbH
Axelar AB
ImmunoFrontier, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.